6 O
ADVERSE O
REACTIONS O
The O
following O
adverse O
reactions O
are O
discussed O
in O
more O
detail O
in O
other O
sections O
of O
the O
labeling O
. O

* O
Cardiomyopathy B-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Related I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
* O
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Foot I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
* O
Secondary B-OSE_Labeled_AE
Oral I-OSE_Labeled_AE
Neoplasms I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
The O
most O
common O
adverse O
reactions O
( O
> O
20 O
% O
) O
observed O
with O
DOXIL O
are O
asthenia B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
fever B-OSE_Labeled_AE
, O
nausea B-OSE_Labeled_AE
, O
stomatitis B-OSE_Labeled_AE
, O
vomiting B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
constipation B-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
and O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
and O
anemia B-OSE_Labeled_AE
. O

EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
> O
20 O
% O
) O
are O
asthenia O
, O
fatigue O
, O
fever O
, O
anorexia O
, O
nausea O
, O
vomiting O
, O
stomatitis O
, O
diarrhea O
, O
constipation O
, O
hand-foot O
syndrome O
, O
rash O
, O
neutropenia O
, O
thrombocytopenia O
, O
and O
anemia O
( O
6 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
contact O
Janssen O
Products O
, O
LP O
at O
1-800-JANSSEN O
( O
1-800-526-7736 O
) O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
. O

6.1 O
Adverse O
Reactions O
in O
Clinical O
Trials O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
the O
adverse O
reaction O
rates O
observed O
can O
not O
be O
directly O
compared O
to O
rates O
on O
other O
clinical O
trials O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
clinical O
practice O
. O

The O
safety O
data O
reflect O
exposure O
to O
DOXIL O
in O
1310 O
patients O
including O
: O
239 O
patients O
with O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
753 O
patients O
with O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
Kaposi I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
sarcoma I-Not_AE_Candidate
, O
and O
318 O
patients O
with O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
. O

The O
following O
tables O
present O
adverse O
reactions O
from O
clinical O
trials O
of O
single-agent O
DOXIL O
in O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
and O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
Related I-Not_AE_Candidate
Kaposi I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
sarcoma I-Not_AE_Candidate
. O

Patients O
With O
Ovarian O
Cancer O
The O
safety O
data O
described O
below O
are O
from O
Trial O
4 O
, O
which O
included O
239 O
patients O
with O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
treated O
with O
DOXIL O
50 O
mg/m O
2 O
once O
every O
4 O
weeks O
for O
a O
minimum O
of O
four O
courses O
in O
a O
randomized O
, O
multicenter O
, O
open-label O
study O
. O

In O
this O
trial O
, O
patients O
received O
DOXIL O
for O
a O
median O
number O
of O
3.2 O
months O
( O
range O
1 O
day O
to O
25.8 O
months O
) O
. O

The O
median O
age O
of O
the O
patients O
is O
60 O
years O
( O
range O
27 O
to O
87 O
) O
, O
with O
91 O
% O
Caucasian O
, O
6 O
% O
Black O
, O
and O
3 O
% O
Hispanic O
or O
Other O
. O

Table O
3 O
presents O
the O
hematologic B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
from O
Trial O
4 O
. O

Table O
3 O
: O
Hematologic O
Adverse O
Reactions O
in O
Trial O
4 O
DOXIL O
Patients O
( O
n=239 O
) O
Topotecan O
Patients O
( O
n=235 O
) O
Neutropenia B-OSE_Labeled_AE
500 O
- O
< O
1000/mm O
3 O
8 O
% O
14 O
% O
< O
500/mm O
3 O
4.2 O
% O
62 O
% O
Anemia B-OSE_Labeled_AE
6.5 O
- O
< O
8 O
g/dL O
5 O
% O
25 O
% O
< O
6.5 O
g/dL O
0.4 O
% O
4.3 O
% O
Thrombocytopenia B-OSE_Labeled_AE
10,000 O
- O
< O
50,000/mm O
3 O
1.3 O
% O
17 O
% O
< O
10,000/mm O
3 O
0.0 O
% O
17 O
% O
Table O
4 O
presents O
the O
non B-NonOSE_AE
- I-NonOSE_AE
hematologic I-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
from O
Trial O
4 O
. O

Table O
4 O
: O
Non-Hematologic O
Adverse O
Reactions O
in O
Trial O
4 O
Non-Hematologic O
Adverse O
Reaction O
10 O
% O
or O
Greater O
DOXIL O
( O
% O
) O
treated O
( O
n=239 O
) O
Topotecan O
( O
% O
) O
treated O
( O
n=235 O
) O
All O
grades O
Grades O
3-4 O
All O
grades O
Grades O
3-4 O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
Asthenia B-OSE_Labeled_AE
40 O
7 O
52 O
8 O
Fever B-OSE_Labeled_AE
21 O
0.8 O
31 O
6 O
Mucous B-OSE_Labeled_AE
Membrane I-OSE_Labeled_AE
Disorder I-OSE_Labeled_AE
14 O
3.8 O
3.4 O
0 O
Back B-OSE_Labeled_AE
Pain I-OSE_Labeled_AE
12 O
1.7 O
10 O
0.9 O
Infection B-OSE_Labeled_AE
12 O
2.1 O
6 O
0.9 O
Headache B-OSE_Labeled_AE
11 O
0.8 O
15 O
0 O
Digestive B-NonOSE_AE
Nausea B-OSE_Labeled_AE
46 O
5 O
63 O
8 O
Stomatitis B-OSE_Labeled_AE
41 O
8 O
15 O
0.4 O
Vomiting B-OSE_Labeled_AE
33 O
8 O
44 O
10 O
Diarrhea B-OSE_Labeled_AE
21 O
2.5 O
35 O
4.2 O
Anorexia B-OSE_Labeled_AE
20 O
2.5 O
22 O
1.3 O
Dyspepsia B-OSE_Labeled_AE
12 O
0.8 O
14 O
0 O
Nervous B-NonOSE_AE
Dizziness B-OSE_Labeled_AE
4.2 O
0 O
10 O
0 O
Respiratory B-NonOSE_AE
Pharyngitis B-OSE_Labeled_AE
16 O
0 O
18 O
0.4 O
Dyspnea B-OSE_Labeled_AE
15 O
4.1 O
23 O
4.3 O
Cough B-OSE_Labeled_AE
increased I-OSE_Labeled_AE
10 O
0 O
12 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
51 O
24 O
0.9 O
0 O
Rash B-OSE_Labeled_AE
29 O
4.2 O
12 O
0.4 O
Alopecia B-OSE_Labeled_AE
19 O
N/A O
52 O
N/A O
The O
following O
additional O
adverse O
reactions O
were O
observed O
in O
patients O
with O
ovarian B-Not_AE_Candidate
cancer I-Not_AE_Candidate
with O
doses O
administered O
every O
four O
weeks O
( O
Trial O
4 O
) O
. O

Incidence O
1 O
% O
to O
10 O
% O
Cardiovascular B-NonOSE_AE
: O
vasodilation B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
deep B-OSE_Labeled_AE
vein I-OSE_Labeled_AE
thrombosis I-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
: O
oral B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
, O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
esophagitis B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
, O
rectal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
, O
ileus B-OSE_Labeled_AE
. O

Hematologic B-NonOSE_AE
and I-NonOSE_AE
Lymphatic I-NonOSE_AE
: O
ecchymosis B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
: O
dehydration B-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
hyperbilirubinemia B-OSE_Labeled_AE
, O
hypokalemia B-OSE_Labeled_AE
, O
hypercalcemia B-OSE_Labeled_AE
, O
hyponatremia B-OSE_Labeled_AE
. O

Nervous B-NonOSE_AE
: O
somnolence B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
depression B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
: O
rhinitis B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
sinusitis B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
pruritus B-OSE_Labeled_AE
, O
skin B-OSE_Labeled_AE
discoloration I-OSE_Labeled_AE
, O
vesiculobullous B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
maculopapular B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
skin I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
, O
fungal B-OSE_Labeled_AE
dermatitis I-OSE_Labeled_AE
, O
furunculosis B-OSE_Labeled_AE
, O
acne B-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
conjunctivitis B-OSE_Labeled_AE
, O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
, O
dry B-OSE_Labeled_AE
eyes I-OSE_Labeled_AE
. O

Urinary B-NonOSE_AE
: O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
infection I-OSE_Labeled_AE
, O
hematuria B-OSE_Labeled_AE
, O
vaginal B-OSE_Labeled_AE
moniliasis I-OSE_Labeled_AE
. O

Patients O
With O
AIDS-Related O
Kaposi O
's O
Sarcoma O
The O
safety O
data O
described O
is O
based O
on O
the O
experience O
reported O
in O
753 O
patients O
with O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
Kaposi I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
sarcoma I-Not_AE_Candidate
( I-Not_AE_Candidate
KS I-Not_AE_Candidate
) O
enrolled O
in O
four O
open-label O
, O
uncontrolled O
trials O
of O
DOXIL O
administered O
at O
doses O
ranging O
from O
10 O
to O
40 O
mg/m O
2 O
every O
2 O
to O
3 O
weeks O
. O

Demographics O
of O
the O
population O
were O
: O
median O
age O
38.7 O
years O
( O
range O
24-70 O
) O
; O
99 O
% O
male O
; O
88 O
% O
Caucasian O
, O
6 O
% O
Hispanic O
, O
4 O
% O
Black O
, O
and O
2 O
% O
Asian/other/unknown O
. O

The O
majority O
of O
patients O
were O
treated O
with O
20 O
mg/m O
2 O
of O
DOXIL O
every O
2 O
to O
3 O
weeks O
with O
a O
median O
exposure O
of O
4.2 O
months O
( O
range O
1 O
day O
to O
26.6 O
months O
) O
. O

The O
median O
cumulative O
dose O
was O
120 O
mg/m O
2 O
( O
range O
3.3 O
to O
798.6 O
mg/m O
2 O
) O
; O
3 O
% O
received O
cumulative O
doses O
of O
greater O
than O
450 O
mg/m O
2 O
. O

Disease O
characteristics O
were O
: O
61 O
% O
poor O
risk O
for O
KS B-Not_AE_Candidate
tumor I-Not_AE_Candidate
burden I-Not_AE_Candidate
, O
91 O
% O
poor O
risk O
for O
immune O
system O
, O
and O
47 O
% O
poor O
risk O
for O
systemic B-Not_AE_Candidate
illness I-Not_AE_Candidate
; O
36 O
% O
were O
poor O
risk O
for O
all O
three O
categories O
; O
median O
CD4 O
count O
21 O
cells/mm O
3 O
( O
51 O
% O
less O
than O
50 O
cells/mm O
3 O
) O
; O
mean O
absolute O
neutrophil O
count O
at O
study O
entry O
approximately O
3,000 O
cells/mm O
3 O
. O

Of O
the O
693 O
patients O
with O
concomitant O
medication O
information O
, O
59 O
% O
were O
on O
one O
or O
more O
antiretroviral O
medications O
[ O
35 O
% O
zidovudine O
( O
AZT O
) O
, O
21 O
% O
didanosine O
( O
ddI O
) O
, O
16 O
% O
zalcitabine O
( O
ddC O
) O
, O
and O
10 O
% O
stavudine O
( O
D4T O
) O
] O
; O
85 O
% O
received O
PCP B-NonOSE_AE
prophylaxis I-NonOSE_AE
( O
54 O
% O
sulfamethoxazole/trimethoprim O
) O
; O
85 O
% O
received O
antifungal O
medications O
( O
76 O
% O
fluconazole O
) O
; O
72 O
% O
received O
antivirals O
( O
56 O
% O
acyclovir O
, O
29 O
% O
ganciclovir O
, O
and O
16 O
% O
foscarnet O
) O
and O
48 O
% O
patients O
received O
colony-stimulating O
factors O
( O
sargramostim/filgrastim O
) O
during O
their O
course O
of O
treatment O
. O

Adverse O
reactions O
led O
to O
discontinuation O
of O
treatment O
in O
5 O
% O
of O
patients O
with O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
Kaposi I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
sarcoma I-Not_AE_Candidate
and O
included O
myelosuppression B-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
infusion B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
toxoplasmosis B-OSE_Labeled_AE
, O
HFS B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
cough B-OSE_Labeled_AE
/ O
dyspnea B-OSE_Labeled_AE
, O
fatigue B-OSE_Labeled_AE
, O
optic B-OSE_Labeled_AE
neuritis I-OSE_Labeled_AE
, O
progression B-OSE_Labeled_AE
of I-OSE_Labeled_AE
a I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
KS I-OSE_Labeled_AE
tumor I-OSE_Labeled_AE
, O
allergy B-Not_AE_Candidate
to I-Not_AE_Candidate
penicillin I-Not_AE_Candidate
, O
and O
unspecified O
reasons O
. O

Tables O
5 O
and O
6 O
summarize O
adverse O
reactions O
reported O
in O
patients O
treated O
with O
DOXIL O
for O
AIDS-related O
Kaposi O
's O
sarcoma O
in O
a O
pooled O
analysis O
of O
the O
four O
trials O
. O

Table O
5 O
: O
Hematologic O
Adverse O
Reactions O
Reported O
in O
Patients O
With O
AIDS-Related O
Kaposi O
's O
Sarcoma O
Patients O
With O
Refractory O
or O
Intolerant O
AIDS-Related O
Kaposi O
's O
Sarcoma O
( O
n=74 O
[ O
note O
: O
This O
includes O
a O
subset O
of O
subjects O
who O
were O
retrospectively O
identified O
as O
having O
disease O
progression O
on O
prior O
systemic O
combination O
chemotherapy O
( O
at O
least O
2 O
cycles O
of O
a O
regimen O
containing O
at O
least O
2 O
of O
3 O
treatments O
: O
bleomycin O
, O
vincristine O
or O
vinblastine O
, O
or O
doxorubicin O
) O
or O
as O
being O
intolerant O
to O
such O
therapy O
. O
] O

) O
Total O
Patients O
With O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
Related I-Not_AE_Candidate
Kaposi I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
Sarcoma I-Not_AE_Candidate
( O
n=720 O
[ O
note O
: O
This O
includes O
only O
subjects O
with O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
KS I-Not_AE_Candidate
who O
had O
available O
data O
from O
the O
4 O
pooled O
trials O
. O
] O

) O
Neutropenia B-OSE_Labeled_AE
< O
1000/mm O
3 O
46 O
% O
49 O
% O
< O
500/mm O
3 O
11 O
% O
13 O
% O
Anemia B-OSE_Labeled_AE
< O
10 O
g/dL O
58 O
% O
55 O
% O
< O
8 O
g/dL O
16 O
% O
18 O
% O
Thrombocytopenia B-OSE_Labeled_AE
< O
150,000/mm O
3 O
61 O
% O
61 O
% O
< O
25,000/mm O
3 O
1.4 O
% O
4.2 O
% O
Table O
6 O
: O
Non-Hematologic O
Adverse O
Reactions O
Reported O
in O
> O
= O
5 O
% O
of O
Patients O
With O
AIDS-Related O
Kaposi O
's O
Sarcoma O
Adverse O
Reactions O
Patients O
With O
Refractory O
or O
Intolerant O
AIDS-Related O
Kaposi O
's O
Sarcoma O
( O
n=77 O
[ O
note O
: O
This O
includes O
a O
subset O
of O
subjects O
who O
were O
retrospectively O
identified O
as O
having O
disease O
progression O
on O
prior O
systemic O
combination O
chemotherapy O
( O
at O
least O
2 O
cycles O
of O
a O
regimen O
containing O
at O
least O
2 O
of O
3 O
treatments O
: O
bleomycin O
, O
vincristine O
or O
vinblastine O
, O
or O
doxorubicin O
) O
or O
as O
being O
intolerant O
to O
such O
therapy O
. O
] O

) O
Total O
Patients O
With O
AIDS-Related O
Kaposi O
's O
Sarcoma O
( O
n=705 O
[ O
note O
: O
This O
includes O
only O
subjects O
with O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
KS I-Not_AE_Candidate
who O
had O
available O
adverse O
event O
data O
from O
the O
4 O
pooled O
trials O
. O
] O

) O
Nausea B-OSE_Labeled_AE
18 O
% O
17 O
% O
Asthenia B-OSE_Labeled_AE
7 O
% O
10 O
% O
Fever B-OSE_Labeled_AE
8 O
% O
9 O
% O
Alopecia B-OSE_Labeled_AE
9 O
% O
9 O
% O
Alkaline B-OSE_Labeled_AE
Phosphatase I-OSE_Labeled_AE
Increase I-OSE_Labeled_AE
1.3 O
% O
8 O
% O
Vomiting B-OSE_Labeled_AE
8 O
% O
8 O
% O
Diarrhea B-OSE_Labeled_AE
5 O
% O
8 O
% O
Stomatitis B-OSE_Labeled_AE
5 O
% O
7 O
% O
Oral B-OSE_Labeled_AE
Moniliasis I-OSE_Labeled_AE
1.3 O
% O
6 O
% O
The O
following O
additional O
adverse O
reactions O
were O
observed O
in O
705 O
patients O
with O
AIDS B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
Kaposi I-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
sarcoma I-Not_AE_Candidate
. O

Incidence O
1 O
% O
to O
5 O
% O
Body B-NonOSE_AE
as I-NonOSE_AE
a I-NonOSE_AE
Whole I-NonOSE_AE
: O
headache B-OSE_Labeled_AE
, O
back B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
infection B-OSE_Labeled_AE
, O
allergic B-OSE_Labeled_AE
reaction I-OSE_Labeled_AE
, O
chills B-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
: O
chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
, O
hypotension B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
. O

Cutaneous B-NonOSE_AE
: O
herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
, O
itching B-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
: O
mouth B-OSE_Labeled_AE
ulceration I-OSE_Labeled_AE
, O
anorexia B-OSE_Labeled_AE
, O
dysphagia B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
: O
SGPT B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
weight B-OSE_Labeled_AE
loss I-OSE_Labeled_AE
, O
hyperbilirubinemia B-OSE_Labeled_AE
. O

Other O
: O
dyspnea B-OSE_Labeled_AE
, O
pneumonia B-OSE_Labeled_AE
, O
dizziness B-OSE_Labeled_AE
, O
somnolence B-OSE_Labeled_AE
. O

Incidence O
Less O
Than O
1 O
% O
Body B-NonOSE_AE
As I-NonOSE_AE
A I-NonOSE_AE
Whole I-NonOSE_AE
: O
sepsis B-OSE_Labeled_AE
, O
moniliasis B-OSE_Labeled_AE
, O
cryptococcosis B-OSE_Labeled_AE
. O

Cardiovascular B-NonOSE_AE
: O
thrombophlebitis B-OSE_Labeled_AE
, O
cardiomyopathy B-OSE_Labeled_AE
, O
palpitation B-OSE_Labeled_AE
, O
bundle B-OSE_Labeled_AE
branch I-OSE_Labeled_AE
block I-OSE_Labeled_AE
, O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
heart B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
thrombosis B-OSE_Labeled_AE
, O
ventricular B-OSE_Labeled_AE
arrhythmia I-OSE_Labeled_AE
. O

Digestive B-NonOSE_AE
: O
hepatitis B-OSE_Labeled_AE
. O

Metabolic B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
Disorders I-NonOSE_AE
: O
dehydration B-OSE_Labeled_AE
. O

Respiratory B-NonOSE_AE
: O
cough B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
, O
pharyngitis B-OSE_Labeled_AE
. O

Skin B-NonOSE_AE
and I-NonOSE_AE
Appendages I-NonOSE_AE
: O
maculopapular B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
. O

Special B-NonOSE_AE
Senses I-NonOSE_AE
: O
taste B-OSE_Labeled_AE
perversion I-OSE_Labeled_AE
, O
conjunctivitis B-OSE_Labeled_AE
. O

Patients O
With O
Multiple O
Myeloma O
The O
safety O
data O
described O
are O
from O
318 O
patients O
treated O
with O
DOXIL O
( O
30 O
mg/m O
2 O
) O
administered O
on O
day O
4 O
following O
bortezomib O
( O
1.3 O
mg/m O
2 O
i.v O
. O

bolus O
on O
days O
1 O
, O
4 O
, O
8 O
and O
11 O
) O
every O
3 O
weeks O
, O
in O
a O
randomized O
, O
open-label O
, O
multicenter O
study O
( O
Trial O
6 O
) O
. O

In O
this O
trial O
, O
patients O
in O
the O
DOXIL O
+ O
bortezomib O
combination O
group O
were O
treated O
for O
a O
median O
number O
of O
4.5 O
months O
( O
range O
21 O
days O
to O
13.5 O
months O
) O
. O

The O
population O
was O
28 O
to O
85 O
years O
of O
age O
( O
median O
age O
61 O
) O
, O
58 O
% O
male O
, O
90 O
% O
Caucasian O
, O
6 O
% O
Black O
, O
and O
4 O
% O
Asian O
and O
Other O
. O

Table O
7 O
lists O
adverse O
reactions O
reported O
in O
10 O
% O
or O
more O
of O
patients O
treated O
with O
DOXIL O
in O
combination O
with O
bortezomib O
for O
multiple B-Not_AE_Candidate
myeloma I-Not_AE_Candidate
. O

Table O
7 O
: O
Frequency O
of O
Treatment-Emergent O
Adverse O
Reactions O
Reported O
in O
> O
=10 O
% O
Patients O
Treated O
for O
Multiple O
Myeloma O
With O
DOXIL O
in O
Combination O
With O
Bortezomib O
Adverse O
Reaction O
DOXIL O
+ O
bortezomib O
( O
n=318 O
) O
Bortezomib O
( O
n=318 O
) O
Any O
( O
% O
) O
Grade O
3-4 O
Any O
( O
% O
) O
Grade O
3-4 O
Blood B-NonOSE_AE
and I-NonOSE_AE
lymphatic I-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Neutropenia B-OSE_Labeled_AE
36 O
32 O
22 O
16 O
Thrombocytopenia B-OSE_Labeled_AE
33 O
24 O
28 O
17 O
Anemia B-OSE_Labeled_AE
25 O
9 O
21 O
9 O
General B-NonOSE_AE
disorders I-NonOSE_AE
and I-NonOSE_AE
administration I-NonOSE_AE
site I-NonOSE_AE
conditions I-NonOSE_AE
Fatigue B-OSE_Labeled_AE
36 O
7 O
28 O
3 O
Pyrexia B-OSE_Labeled_AE
31 O
1 O
22 O
1 O
Asthenia B-OSE_Labeled_AE
22 O
6 O
18 O
4 O
Gastrointestinal B-NonOSE_AE
disorders I-NonOSE_AE
Nausea B-OSE_Labeled_AE
48 O
3 O
40 O
1 O
Diarrhea B-OSE_Labeled_AE
46 O
7 O
39 O
5 O
Vomiting B-OSE_Labeled_AE
32 O
4 O
22 O
1 O
Constipation B-OSE_Labeled_AE
31 O
1 O
31 O
1 O
Mucositis B-OSE_Labeled_AE
/ O
Stomatitis B-OSE_Labeled_AE
20 O
2 O
5 O
< O
1 O
Abdominal B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
11 O
1 O
8 O
1 O
Infections B-NonOSE_AE
and I-NonOSE_AE
infestations I-NonOSE_AE
Herpes B-OSE_Labeled_AE
zoster I-OSE_Labeled_AE
11 O
2 O
9 O
2 O
Herpes B-OSE_Labeled_AE
simplex I-OSE_Labeled_AE
10 O
0 O
6 O
1 O
Investigations B-NonOSE_AE
Weight B-OSE_Labeled_AE
decreased I-OSE_Labeled_AE
12 O
0 O
4 O
0 O
Metabolism B-NonOSE_AE
and I-NonOSE_AE
Nutritional I-NonOSE_AE
disorders I-NonOSE_AE
Anorexia B-OSE_Labeled_AE
19 O
2 O
14 O
< O
1 O
Nervous B-NonOSE_AE
system I-NonOSE_AE
disorders I-NonOSE_AE
Peripheral B-OSE_Labeled_AE
Neuropathy I-OSE_Labeled_AE
[ O
note O
: O
Peripheral B-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
includes O
the O
following O
adverse O
reactions O
: O
peripheral B-OSE_Labeled_AE
sensory I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
neuropathy B-OSE_Labeled_AE
peripheral I-OSE_Labeled_AE
, O
polyneuropathy B-OSE_Labeled_AE
, O
peripheral B-OSE_Labeled_AE
motor I-OSE_Labeled_AE
neuropathy I-OSE_Labeled_AE
, O
and O
neuropathy B-OSE_Labeled_AE
NOS O
. O
] O

42 O
7 O
45 O
11 O
Neuralgia B-OSE_Labeled_AE
17 O
3 O
20 O
4 O
Paresthesia B-OSE_Labeled_AE
/ O
dysesthesia B-OSE_Labeled_AE
13 O
< O
1 O
10 O
0 O
Respiratory B-NonOSE_AE
, I-NonOSE_AE
thoracic I-NonOSE_AE
and I-NonOSE_AE
mediastinal I-NonOSE_AE
disorders I-NonOSE_AE
Cough B-OSE_Labeled_AE
18 O
0 O
12 O
0 O
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
Rash B-OSE_Labeled_AE
[ O
note O
: O
Rash B-OSE_Labeled_AE
includes O
the O
following O
adverse O
reactions O
: O
rash B-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
erythematous I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
macular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
maculo I-OSE_Labeled_AE
- I-OSE_Labeled_AE
papular I-OSE_Labeled_AE
, O
rash B-OSE_Labeled_AE
pruritic I-OSE_Labeled_AE
, O
exfoliative B-OSE_Labeled_AE
rash I-OSE_Labeled_AE
, O
and O
rash B-OSE_Labeled_AE
generalized O
. O
] O

22 O
1 O
18 O
1 O
Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
19 O
6 O
< O
1 O
0 O
6.2 O
Postmarketing O
Experience O
The O
following O
additional O
adverse O
reactions O
have O
been O
identified O
during O
post O
approval O
use O
of O
DOXIL O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

Musculoskeletal B-NonOSE_AE
and I-NonOSE_AE
Connective I-NonOSE_AE
Tissue I-NonOSE_AE
Disorders I-NonOSE_AE
: O
muscle B-OSE_Labeled_AE
spasms I-OSE_Labeled_AE
Respiratory B-NonOSE_AE
, I-NonOSE_AE
Thoracic I-NonOSE_AE
and I-NonOSE_AE
Mediastinal I-NonOSE_AE
Disorders I-NonOSE_AE
: O
pulmonary B-OSE_Labeled_AE
embolism I-OSE_Labeled_AE
( O
in O
some O
cases O
fatal B-NonOSE_AE
) O
Hematologic B-NonOSE_AE
disorders I-NonOSE_AE
: O
Secondary B-OSE_Labeled_AE
acute I-OSE_Labeled_AE
myelogenous I-OSE_Labeled_AE
leukemia I-OSE_Labeled_AE
Skin B-NonOSE_AE
and I-NonOSE_AE
subcutaneous I-NonOSE_AE
tissue I-NonOSE_AE
disorders I-NonOSE_AE
: O
erythema B-OSE_Labeled_AE
multiforme I-OSE_Labeled_AE
, O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
, O
toxic B-OSE_Labeled_AE
epidermal I-OSE_Labeled_AE
necrolysis I-OSE_Labeled_AE
Secondary B-OSE_Labeled_AE
oral I-OSE_Labeled_AE
neoplasms I-OSE_Labeled_AE
: O
[ O
see O
Warnings O
and O
Precautions O
( O
5.4 O
) O
] O
. O

